Abnormal FOXD1 expression is involved in the progression of tumors including colorectal cancer [26], melanoma, breast cancer [27], glioma [28], osteosarcoma, renal cell carcinoma, medulloblastoma ovarian carcinoma, [29], and lung cancer [30]. This evidence concerns the gene FOXD1 and breast carcinoma.